(Reuters) - Abbott Laboratories reported better than expected quarterly earnings despite disrupted sales of its infant formulas in China, helped by cost cuts and lower taxes.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
Abbott shares rose 1.7 percent in premarket trading.
The company, which spun off its branded prescription drugs business in January into a separate publicly traded company called AbbVie Inc, on Wednesday reported third-quarter earnings from continuing operations of $773 million, or 49 cents per share. That compared with $339 million, or 21 cents per share, in the year-earlier period.
Excluding special items, Abbott earned 55 cents per share. Analysts, on average, had expected 51 cents per share.
Global company revenue rose 2 percent to $5.37 billion, a bit shy of Wall Street forecasts of $5.39 billion.
Despite beating earnings forecasts in the quarter, Abbott stuck to its prior full-year profit view of $1.98 per share to $2.04 per share, excluding special items.
But the suburban Chicago company, which also makes diagnostics, medical devices and generic medicines, said it was increasing its quarterly dividend by 57 percent to 22 cents per share from 14 cents, starting with the February 15 payment.
(Reporting by Ransdell Pierson; Editing by Gerald E. McCormick)
(c) Copyright Thomson Reuters 2013. Check for restrictions at: http://about.reuters.com/fulllegal.asp